Loading…

Aluminium Interference in the Treatment of Haemodialysis Patients with Recombinant Human Erythropoietin

In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided intotwo groups. Group A comprised five patients with a greater mean alum...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 1990, Vol.5 (6), p.441-443
Main Authors: Casati, S., Castelnovo, Claudia, Campise, Mariarosaria, Ponticelli, C.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided intotwo groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/1) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14–39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/1) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed.The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/1; P
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/5.6.441